cabergoline (Dostinex)
Jump to navigation
Jump to search
Introduction
Tradename: Dostinex.
Indications
- treatment of hyperprolactinemia
- idiopathic
- secondary to pituitary adenoma
Contraindications
- uncontrolled hypertension
- hypersensitivity to ergot alkaloids
Dosage
- start 0.25 mg twice weekly
- increase by 0.25 mg up no more than every 4 weeks to 1 mg twice weekly
- titrate to serum prolactin
- when serum prolactin maintained for 6 months, discontinue & monitor serum prolactin to determine if cabergoline still needed
Tabs: 0.5 mg.
Adverse effects
- common (> 10%)
- less common (1-10%)
- asthenia, fatigue, syncope (1%), flu-like syndrome (1%), malaise, periorbital edema, peripheral edema, hot flashes, hypotension, palpitation, vertigo, paresthesias, acne, pruritus, breast pain (2%), dysmenorrhea, constipation, abdominal pain, dyspepsia, vomiting, dry mouth, diarrhea, flatulence, throat irritation, toothache, pain, arthralgia, visual disturbances, depression, somnolence, anorexia, anxiety, insomnia, impaired concentration, nervousness, rhinitis
- valvular heart disease
- aortic regurgitation (RR = 7.3)[3]
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of dopaminergic receptor agonists
- drug adverse effects of sympathomimetic(s)
Drug interactions
- additive effects with antihypertensive medications
- dopamine antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide) antagonize therapeutic effects of cabergoline
- cabergoline can induce psychosis in patients receiving antipsychotics
Mechanism of action
More general terms
Additional terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 3.0 3.1 Schade R et al, Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 Jan 4; 356:29-38
Zanettini R et al, Valvular heart disease during treatment with dopamine agonists for Parkinson's disease. N Engl J Med 2007 Jan 4; 356:39-46 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17202454
Roth BL. Drugs and valvular heart disease. N Engl J Med 2007 Jan 4; 356:6-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17202450
Prescriber's Letter 14(2): 2007 Drug-induced heart valve dysfunction Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230206&pb=PRL (subscription needed) http://www.prescribersletter.com